Mergers and Acquisitions - Additional Information (Detail) - USD ($)			1 Months Ended	6 Months Ended
		Dec. 08, 2017	Mar. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 9.91		$ 9.75
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	[1]			6,109,205
Payments for Agreement Termination				$ 400,000
Goodwill, Period Increase (Decrease)				242,456
Goodwill, Purchase Accounting Adjustments				671,555
Purchase Price Adjustment for Acceleration of Vested Stock Options				868,000	$ 0
Goodwill, Subsequent Recognition of Deferred Tax Asset				196,445
Goodwill Decrease Merger Transaction Costs				914,011
Preferred Stock [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	[2]			$ 19,118,000
APA ACO, Inc [Member]
Equity Method Investment, Ownership Percentage				50.00%
Network Medical Management, Inc. [Member]
Payments for Agreement Termination				$ 400,000
Network Medical Management, Inc. [Member] | Noncontrolling Interest [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	[3]			$ 5,129,000
Network Medical Management, Inc. [Member] | APA ACO, Inc [Member]
Equity Method Investment, Ownership Percentage				50.00%
Apollo Medical Holdings, Inc [Member]
Business Combination, Step Acquisition, Equity Interest in Acquire, Number of Share		2,566,666
Business Acquisition, Percentage of Voting Interests Acquired		82.00%
Business Combination, Consideration Description				The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 shares (immediately following the Merger).
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		6,109,205
Fair Value Assumption Expected Term				2 years
Fair Value Assumption Expected Volatility Rate				37.90%
Fair Value Assumption Risk Free Interest Rate				1.80%
Preferred Stock, Liquidation Preference, Value				$ 12,745,000
Apollo Medical Holdings, Inc [Member] | Convertible Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued			520,081
Debt Conversion, Converted Instrument, Amount			$ 4,990,000
Apollo Medical Holdings, Inc [Member] | Warrant One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		850,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 11.00
Apollo Medical Holdings, Inc [Member] | Warrant Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		900,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10.00
Maverick Medical Group, Inc [Member]
Business Combination, Contingent Consideration, Asset				100
Common Class B [Member] | Apollo Medical Holdings, Inc [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value				$ 6,373,000

[1] Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.

[2] NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (“OPM”) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.

[3] Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior to the Merger.